Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.48 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | DMPK | Q09013 | 1/20 | 0.41 |
| ▸ | MYLK | Q15746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511581 | 0.92 | ROCK1 (0.50) | ROCK1ROCK2RORCTRPV1NAMPT | |
| SCHEMBL3512717 | 0.91 | ROCK2 (0.47) | ROCK1ROCK2RORCMAPTNAMPT | |
| SCHEMBL3512328 | 0.91 | ROCK1 (0.41) | ROCK1ROCK2RORCALDH1A1TRPV1 | |
| SCHEMBL3508218 | 0.91 | ROCK1 (0.48) | ROCK1ROCK2RORCTRPV1CLK1 | |
| SCHEMBL3512275 | 0.90 | ROCK1 (0.51) | ROCK1ROCK2RORCNAMPTGSK3B | |
| SCHEMBL3513516 | 0.90 | ROCK2 (0.50) | ROCK1ROCK2TRPV1MAPTNAMPT | |
| SCHEMBL3512613 | 0.90 | RORC (0.41) | ROCK1ROCK2RORCTRPV1NAMPT | |
| SCHEMBL3513135 | 0.90 | ROCK1 (0.49) | ROCK1ROCK2ALDH1A1TRPV1MAPT | |
| SCHEMBL3513182 | 0.88 | NAMPT (0.42) | ROCK1ROCK2RORCNAMPTAKT1 | |
| SCHEMBL3513585 | 0.87 | ROCK1 (0.54) | ROCK1ROCK2ALDH1A1MAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | claimed |
| WO-2009015193-A1 | ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009015193-A1 | ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | TST, UMPS, UROD | ROCK1 4658/4885ROCK2 4700/4885RORC 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.